KAREN CHEEK: Open Payments
NPI 1316052442 · MANCHESTER, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$419 in 20 payments from 9 companies in 2025. Trend: 2023 $101 · 2024 $255 · 2025 $419
Food & beverage: $419
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $156 |
| Vanda Pharmaceuticals Inc. | 2 | $67 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| KYOWA KIRIN, INC. | 1 | $22 |
| Janssen Pharmaceuticals, Inc | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
Products named: VRAYLAR, CAPLYTA, HETLIOZ, FANAPT, REXULTI, CRYSVITA, SPRAVATO, QULIPTA.
Industry payments across KY — which companies pay providers there.
